Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
Global Biosimilars of Factor X agonists Industry Growth and Trends Forecast to 2031
... CAGR of xx% during the forecast period 2026-2031. North American market for Biosimilars of Factor X agonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR ... Read More
-
Global Biosimilars of Factor X agonists Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
... % during the forecast period. The US & Canada market for Biosimilars of Factor X agonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of ... Read More
-
Global Biosimilars of Factor X agonists Market Outlook and Growth Opportunities 2025
... % during the forecast period. The North American market for Biosimilars of Factor X agonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % ... Read More
-
The 2026-2031 World Outlook for Biosimilar Drugs
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Generic Biosimilars
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Biosimilars
... millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project ... Read More
-
The 2026-2031 World Outlook for Biosimilars and Follow-on Biologics
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for Erythropoietin Stimulating Agents
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Erythropoietin Drugs
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Erythropoietins
... millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project ... Read More
-
The 2026-2031 World Outlook for Generic Biosimilar Large Molecule Injectables
... country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using ... Read More
-
The 2026-2031 World Outlook for Biosimilars and Related Biologics
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for Biosimilars and Follow-on Biologics Drugs
... country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using ... Read More
-
The 2026-2031 World Outlook for Biosimilar Monoclonal Antibodies
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Biobetters - High Efficiency and Economical Costs Foster Adoption
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2026-2031 World Outlook for Biosimilar Monoclonal Antibodies (mAb)
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
... been predominantly fueled by heightened awareness and education regarding the safety, efficacy, and interchangeability of biosimilar products. Additionally, favorable insurance coverage and reimbursement structures implemented by both public and private payers have played a crucial ... Read More
-
Gastroenterology Market, By Drug Type (Biologics/Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Others), By Dosage Form (Oral, Parenteral, Others), By Disease Type (Inflammatory Bowel Diseases (IBD), Crohn\\\\s Disease, Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)
... gastrointestinal endoscopy devices along with development of novel drugs for gastrointestinal issues can also drive the market growth. Various market players are engaged in new product launches and expansions to cater to increasing needs of ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Biosimilars
... 20.0% over the analysis period 2024-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$62.4 Billion by the end of the analysis period. ... Read More
-
Erythropoietin Drugs
... CAGR of 4.3% over the analysis period 2024-2030. Epoetin-alfa, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$9.2 Billion by the end of the analysis period. ... Read More
-
PEGylated Proteins
... CAGR of 9.1% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the analysis period. ... Read More
-
Brazil Biosimilars Market Overview, 2030
... one of the biggest and most complicated healthcare systems in the region. The service industry makes up the majority of Brazil's economy, contributing to over 70% of its GDP. Public and commercial healthcare services are ... Read More
-
India Biosimilars Market Overview, 2030
... cannot replicate their reference biologics precisely due to inherent biological complexity and variability. In India, the adoption of biosimilars has gained momentum, with significant contributions to healthcare accessibility and affordability, backed by robust regulatory frameworks ... Read More
-
Europe Biosimilars Market Outlook, 2030
... first biosimilar approval in 2006. Since then, the European market has demonstrated robust growth in biosimilar uptake, driven by an aging population, increasing healthcare costs, and the need for affordable treatment options for chronic and ... Read More
Research Assistance
